Business
Notice of AGM & Publication of 2025 Annual Report
Abingdon Health plc has announced that its Annual General Meeting will be held on Wednesday, December 10, 2025, at 12:00 GMT, and the company has also published its 2025 Annual Report. Printed copies of both documents have been sent to shareholders who receive paper communications, and they will soon be available on the company's website. Disclaimer*
About this update from Abingdon Health Plc
[{"type":"text","content":"\n\n \nAbingdon Health plc\n(\"Abingdon Health\", the \"Group\" or the \"Company\")\n \nNotice of Annual General Meeting\n&\n Publication of 2025 Annual Report\n \nYork, U.K. 14 November 2025: Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and regulatory services provider for rapid tests and med-tech, announces that its Annual General Meeting ('AGM') will be held on Wednesday 10 December 2025 at 12.00 GMT at the Company's offices at York Biotech Campus, Sand Hutton, York, YO41 1LZ, United Kingdom.\n \nPrinted copies of the Notice of the AGM and 2025 Annual Report have been posted to registered shareholders who have elected to receive paper communications and will shortly be available on the Company's website www.abingdonhealth.com.\n \nEnquiries:\n \n\n\n\n\n Abingdon Health plc\n\n\nwww.abingdonhealth.com/investors/\n\n\n\n\n Chris Hand, Executive Chairman\n\n\nVia Walbrook PR\n\n\n\n\n Tom Hayes, CFO\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Zeus (Sole Broker and Nominated Adviser)\n\n\n Tel: +44 (0)20 3829 5000\n\n\n\n\n Antonio Bossi / Jacob Walker (Corporate Finance)\n\n\n\n\n\n\n\n Nick Searle/Fraser Marshall (Corporate Broking)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n Walbrook PR (Media & Investor Relations)\n\n\n Tel: +44 (0)20 7933 8780 or [email protected]\n\n\n\n\n Paul McManus / Alice Woodings\n\n\nMob: +44 (0)7980 541 893 / +44 (0)7407 804 654\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \nAbout Abingdon Health plc\nAbingdon Health Group is a leading med-tech contract service provider offering its services to an international customer base. \n \nThe Group's CDMO expertise offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine manufacturing; fro...